Glooko - Mobile Insulin Dosing System (MIDS)

Provides advanced decision support to optimize doses: FDA-cleared Digital Therapeutics; System provides insulin adjustment recommendations for patients based on the parameters set by the provider; Dose adjustment checks every 1-7 days per treatment plan to get the patient into range; Prescribe to help people with type 2 diabetes determine their optimal long-acting insulin (LAI) dose; Clinicians can remotely monitor patients on the MIDS and provide support as necessary.